Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer, shared a post on LinkedIn:
“Do we need to add chemotherapy to immunotherapy for patients with PD-L1–high (>50%) advanced NSCLC?
Out now in JAMA Oncology, our systematic review and meta-analysis evaluated 24 phase 3 randomized clinical trials including 5,546 patients with PD-L1–high NSCLC.
Using complementary analytic approaches, including meta-regression, network meta-analysis, and reconstructed individual patient data analysis, chemoimmunotherapy was consistently associated with improved overall survival and progression-free survival compared with PD-(L)1 inhibitor monotherapy.
These findings support considering first-line chemoimmunotherapy for selected patients with PD-L1–high NSCLC, particularly those who are fit for chemotherapy and may benefit from a more intensive upfront approach.”
Title: PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression, A Systematic Review and Meta-Analysis
Authors: Alessandro Di Federico, Samuele Compagno, Francesco Mantuano, Sara Stumpo, Andrea De Giglio, Federica Pecci, Joao Alessi, Xinan Wang, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Maria Pantaleo, Andrea Arfè, Hossein Borghaei, Marina Garassino, Federico Cappuzzo, Andrea Ardizzoni, Mark Awad, Biagio Ricciuti
Read the Full Article.
Other Articles Featuring Biagio Ricciuti On OncoDaily.